Acute coronary syndrome and myocardial infarction
98 results
1 - 98Acute coronary syndrome and myocardial infarction
Diagnostic coronary angiography
Coronary heart disease
Pain severity does not predict outcomes with AMI
For treatment of acute coronary syndrome, prasugrel is better than ticagrelor at preventing recurrent MIs at 1 year
High-sensitivity troponin I of less than 5 ng/L has negative predictive value of 99.9% for cardiac death at 1 year
Bivalirudin = abciximab + heparin for non-STEMI
Drug-eluting stents versus bare-metal stents for acute coronary syndrome: Cochrane systematic review
Statins for acute coronary syndrome
Routine or selective invasive strategy for acute coronary syndrome
Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
Patients with non-ST-elevation acute coronary syndromes do not need immediate intervention
Signs and symptoms not helpful in diagnosis of AMI/ACS
Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
Dyspepsia
Escitalopram reduces risk of adverse cardiac events in adults with depression and acute coronary syndrome
Apixaban increases bleeding with no benefit in high-risk patients with ACS
Coronary CT angiogram allows for safe discharge of low-risk patients with chest pain
Statins for acute coronary syndrome Stable (no update expected for reasons given in 'What's new')
Hyperbaric oxygen therapy for acute coronary syndrome New search for studies and content updated (no change to conclusions)
Similar outcomes after PCI in hospitals with or without on-site cardiac surgery (CPORT-E)
Exercise stress test
Antiplatelet agents for chronic kidney disease Edited (no change to conclusions)
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes: Cochrane systematic review
Accelerated protocol identifies chest pain patients at low risk for major cardiac events
Pioglitazone for type 2 diabetes mellitus
In ACS, 5 yrs of invasive tx decreases MI but not all cause mortality (FRISC-II)
Additional testing of limited benefit in patients with new-onset chest pain
Two-hour protocol identifies patients at low risk of ACS
Adding CCTA to chest pain assessment reduces likelihood of nonfatal MI (SCOT-HEART)
Intensive lipid lowering reduces mortality following ACS
Platelet-function testing doesn't improve outcomes in elderly patients with stents after ACS
Single nondetectable high-sensitivity troponin result rules out AMI
Flu vaccine reduces risk of adverse CV events in high-risk patients
ACC/AHA guidelines on dual antiplatelet therapy
Dabigatran associated with increased risk of coronary events
Pioglitazone does not increase cardiovascular events (PROactive)
Low-dose rivaroxaban improves outcomes in patients with ACS (ATLAS)
Warfarin therapy
FDA: Clopidogrel/aspirin does not decrease overall mortality
Genotype-guided selection of oral P2Y12 inhibitor therapy no better than standard therapy after PCI for ACS or stable CAD
Low HS-troponin I accurate in identifying patients at low risk of cardiac events
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
Acute abdomen in the adult
Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes: Cochrane systematic review
CCTA reduces need for hospitalization in low to moderate risk patients in ED
Improved outcomes with early invasive strategy for ACS? Maybe, maybe not.
Better medication adherence with intervention; clinical outcomes unchanged
Ticagrelor (Brilinta) is no better than aspirin—and may be worse—for adults after CABG
Dyspnoea
For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease New search for studies and content updated (conclusions changed)
Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion: Cochrane systematic review
Early invasive therapy better for non-ST ACS
6-month clopidogrel better than 24 after stent placement (PRODIGY)
ED chest pain protocol is safe and efficient
B vitamins, fish oil do not prevent CV events
Interpretation of adult ECG
In patients with vascular disease, treating sleep apnea does not reduce the risk of cardiovascular events
Little if any benefit to early invasive strategy for stable angina and at least moderate reversible ischemia (ISCHEMIA trial)
Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome: Cochrane systematic review
SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
Increased readmissions and adverse events with intensification of antihypertensive regimen on hospital discharge
Syncope: causes and investigations
SBP of 120 instead of 140 in adults 75 years or older = significant benefits and some harms (SPRINT)
Management of acute atrial fibrillation
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events: Cochrane systematic review
Prehospital emergency care
Overview of new ACC/AHA lipid guidelines: here we go again
The most common types of acquired adult valvular heart diseases and associated murmurs